Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2017 Jul;15(7):689-701. doi: 10.1080/14787210.2017.1333422. Epub 2017 May 29.

An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.

Author information

1
a VisMederi Srl , Siena , Italy.
2
b Department of Life Sciences , University of Siena , Siena , Italy.
3
c GSK Vaccines , Siena , Italy.
4
d Department of Molecular and Developmental Medicine , University of Siena , Siena , Italy.

Abstract

Invasive Meningococcal Disease (IMD) represents a potentially life-threatening condition caused by Neisseria meningitidis. The disease is characterized by a case fatality rate of 5-10% whereas serious clinical sequelae can develop in survivors within 12-24 h from the first symptoms. However, IMD infection only occurs rarely, in fact, most of the interactions established between N. meningitidis and the host are harmless, and an estimated 10% of the population asymptomatically carries the bacterium in the nasopharynx. Meningococcal carriage represents a critical condition for IMD onset since it represents the first step for disease transmission. Furthermore, high levels of carriage can promote genetic recombination among different N. meningitidis strains potentially leading to the development of new pathogenic variants. Areas covered: The present review discusses N. meningitidis carriage, factors able to influence meningococcal carriage and disease and the effect of vaccinations on both conditions, with a particular focus on Italy. Expert commentary: Data regarding the effect of different meningococcal vaccines on N. meningitidis carriage are available, whereas further studies are needed to investigate the positive impact of the two recently licensed vaccines 4CMenB and rLP2086 on meningococcal carriage.

KEYWORDS:

Invasive meningococcal disease; Italy; Neisseria meningitidis; meningococcal carriage; meningococcal vaccines; risk factors

PMID:
28524748
DOI:
10.1080/14787210.2017.1333422
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center